skip to Main Content

New Sequencing Strategies Could Hold Key to Improved Outcomes Across GI Malignancies

Newsfeed image, light gray text on dark gray background
With an influx of new therapeutic developments across gastrointestinal (GI) cancers on the horizon, new strategies around the sequencing of available regimens will be key to improving patient outcomes, according to Heloisa P. Soares, MD, PhD.

“There will be a lot of excitement for pancreatic cancer [in the future], although we are not quite there yet,” Soares said. “There are there are many new strategies [in development for other gastrointestinal malignancies] including a whole new role for immunotherapy plus or minus chemotherapy in the up-front treatment of [patients with] metastatic disease, as well as in the adjuvant setting.” Read more . . . 


Back To Top